跳至主要内容
临床试验/NCT01703832
NCT01703832已完成1 期

Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Open-Label Study in Healthy Probands

Biologische Heilmittel Heel GmbH2 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
65
试验地点
2
主要终点
Acute Stress Measured by Tension

研究概览

简要总结

The purpose of this study is to explore the efficacy of acutely dosed Neurexan using an experimental stress test called the Trier Social Stress Test

详细描述

An acute stress reaction is a biopsychological condition arising in response to an event which is individually regarded as emotionally stressful. The onset of a stress response is associated with specific physiological actions in the sympathetic nervous system, both directly and indirectly through the release of adrenaline and to a lesser extent noradrenaline from the medulla of the adrenal glands. These catecholamine hormones facilitate immediate physical reactions by triggering increases in heart rate and breathing, constricting blood vessels. The other major player in the acute stress response is the hypothalamic-pituitary-adrenal axis.

Although stress has been described as a non-specific psychophysiological response to environmental stimuli, it is possible to discern specific bodily stress responses caused by specific emotional reactions to novel, ambivalent or uncontrollable situations and stimuli. For example, social stress induces elevated cortisol levels, particularly if the stressor is uncontrollable, unpredictable, and constitutes a social-evaluative threat due to the judgment of others such as in the Trier Social Stress Test). Usually, the TSST induces a two-fold increase in saliva cortisol with peaks around 10-20 min. after stress test termination. Also, an average increase in heart rates of around 20 beats per minute (bpm) is observed during the TSST. In addition, emotional states and feelings have been shown to be affected by this stress test, such as marked increases in stress perception,anxiety and emotional insecurity as well as decreases in mood, calmness and feeling awake.

Preliminary results indicate that Neurexan® may improve coping abilities in stressful situations. This study aims to investigate the effect of Neurexan® on subjectively perceived nervousness and tension during an acute stressful situation and to characterize the efficacy profile of Neurexan®.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
31 Years 至 59 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Provide written informed consent
  • Healthy male or female
  • age between 31 to 59 years
  • Fluent in German language.
  • Ability to understand the explanations and instructions given by the study physician

排除标准

  • allergies to ingredients of Neurexan® (Passiflora incarnata, Avena sativa, Coffea arabica, Zincum isovalerianicum, lactose monohydrate, magnesium stearate)
  • lactose intolerance
  • use of any psychological stress-management intervention within the last 4 weeks
  • sick leave for any reason
  • participation in any other clinical study 3 months prior to Screening Visit
  • current or recent (3 months prior to Screening Visit) history of substance abuse or drug dependence including nicotine and alcohol (as verified in the respective IDCL list)
  • alcohol intake within last 24 hours (before Baseline Visit V3)
  • shift workers or work regularly during night time
  • use of any psychotropic medication or suffering from severe psychiatric illness needing acute intervention
  • BMI > 30 kg/m2
  • currently pregnant (verified by urine pregnancy test) or lactating
  • participation in a previous TSST study
  • high chronic stress as verified with the TICS-SSCS (a score of ≥ 23 on the screening scale for chronic stress meets the criterion of being chronically stressed)
  • major mental disorder as verified with the IDCL (depressive episode, panic disorder, social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia and mania.)
  • employee of the Sponsor, one of the investigators or the CRO
  • use of any concomitant medication except contraceptives
  • any somatic disease or other condition the Investigator or their duly assigned representatives believes may affect the ability of the individual to complete the study or the interpretation of the study results
  • Individuals whose ability to speak for themselves lacks or can be doubted

研究组 & 干预措施

Neurexan®

Experimental

0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes

干预措施: Neurexan® (Drug)

结局指标

主要结局

Acute Stress Measured by Tension

时间窗: -210 minutes to +100 minutes

Tension and nervousness were self-assessed by the participants on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS) before and after a stress test. The VAS is used to determine the subjective impression of tension and nervousness on a 10 cm bipolar visual scale ranging from 0 = "not at all" to 100 = "highly". The measurements started with first intake of Neurexan or Natural Course and were repeated until 100 minutes after the end of the stress test. The total stress was then summarized with the Area under the curve (AUC) method.

Acute Stress Measured by Nervousness

时间窗: -210 minutes to +100 minutes

Tension and nervousness were self-assessed by the participants on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS) before and after a stress test. The VAS is used to determine the subjective impression of tension and nervousness on a 10 cm bipolar visual scale ranging from 0 = "not at all" to 100 = "highly". The measurements started with first intake of Neurexan or Natural Course and were repeated until 100 minutes after the end of the stress test. The total stress was then summarized with the Area under the curve (AUC) method.

次要结局

  • Changes in Saliva Alpha Amylase(-60 minute, +15 minute , + 45 minute, +100 minute)
  • Changes in Saliva Cortisol(-60 minutes, +15 minutes, +45 minutes, +100 minutes)
  • Psychological Questionnaire (Modified Somatic SCL90)(-210 minutes, +100 minutes)
  • Changes in Plasma Adrenocorticotropic Hormone (ACTH)(-60 minutes, +15 minutes, +45 minutes, +100 minutes)
  • Changes in Plasma Cortisol(-60 minutes, +15 minutes, +45 minutes, +100 minutes)
  • Changes in Plasma Catecholamines (Epinephrine)(-60 minutes, +15 minutes, +45 minutes, +100 minutes)
  • Changes in Natural Killer (NK) Cells (Subgroup)(-60 minutes, +15 minutes, +45 minutes, +100 minutes)
  • Changes in Heart Rate(-15 minutes, 0 minutes, +15 minutes, +45 minutes)
  • State Anxiety and Stress Perception Measured by STAI-X1(-90 minutes, +15 minutes, +100 minutes)
  • Changes in Plasma Catecholamines (Norepinephrine)(-60 minutes, +15 minutes, +45 minutes, +100 minutes)
  • Changes in Blood Pressure(-15 minutes, 0 minutes, +15 minutes, +45 minutes)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验